Abstract
The study of perinatal mental health (mental health during pregnancy and postpartum) is a complex field of study that is of major importance both for the mental and physical health of new mothers and for the neurobehavioral development and long-term functioning of the children they bear. In this review, we cover the most recent additions to this rapidly evolving field. Notable advances include further illumination of the epidemiological patterns and clinical manifestations of perinatal mood disruption; new efficacy data on treatment and prevention; clarifications of the respective contributions of maternal mental illness and psychotropic medication to outcomes of pregnancy, birth, and child development; and updated expert guidelines for screening.
Highlights
The most recent advances in the study of perinatal mental health fall into several categories
Part IV: Recent advances in acute pharmacologic and psychotherapy treatment of perinatal mood disorders A meta-analysis of 40 randomized studies of cognitive behavior therapy (CBT) during pregnancy and the first year postpartum reported that CBT was associated with significant reduction in depressive symptoms[51]
Summary and conclusions The most recent updates in the field of perinatal mental health highlight the importance of risk factors such as BDs, anxiety disorders, attachment insecurity, and neuroticism
Summary
The most recent advances in the study of perinatal mental health fall into several categories. Part IV: Recent advances in acute pharmacologic and psychotherapy treatment of perinatal mood disorders A meta-analysis of 40 randomized studies of cognitive behavior therapy (CBT) during pregnancy and the first year postpartum reported that CBT was associated with significant reduction in depressive symptoms[51]. Larger and more carefully controlled studies of long-term neurodevelopmental outcomes in children are lacking, so for mood stabilizers and antipsychotics Another unanswered question concerns the potential utility of tapering or briefly discontinuing antidepressants toward the end of pregnancy, as the most well-established adverse effects of medication (reduced term of gestation, pulmonary hypertension of the newborn, and neonatal adaptation) are all associated with third-trimester exposure. Grant information The author(s) declared that no grants were involved in supporting this work
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
